Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jean Philippe Capron
Mean Cost Per Number Needed to Treat of Baricitinib Versus Adalimumab in the Treatment of Rheumatoid Arthritis in Italy
Global and Regional Health Technology Assessment
Health Policy
Related publications
Mean Cost Per Number Needed to Treat With Tocilizumab Plus Methotrexate Versus Abatacept Plus Methotrexate in the Treatment of Rheumatoid Arthritis in Patients Previously Treated With Methotrexate
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Adalimumab in the Treatment of Early Rheumatoid Arthritis
Nauchno-Prakticheskaya Revmatologiya
Rheumatology
Allergy
Immunology
Number Needed to Treat in COPD: Exacerbations Versus Pneumonias
Thorax
Pulmonary
Respiratory Medicine
Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Arthritis and Rheumatology
Rheumatology
Allergy
Immunology
Cost Per Responder of Apremilast Versus Etanercept and Adalimumab in Patients With Active Psoriatic Arthritis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of Abatacept Compared to Adalimumab in Italy Based on a Head-To-Head Outcomes Study in Rheumatoid Arthritis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms47 - Cost-Effectiveness of Tofacitinib Compared With Adalimumab in the Treatment of Moderate to Severe Rheumatoid Arthritis in Iran
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
